Phillip Wall , Wes Tucker , Thomas Mazur, Frank Marshall, Jonathan Pence, Jon Hansen, Michael Prusator, Matthew Schmidt, Nels Knutson
{"title":"利用二次蒙特卡罗剂量计算立体定向放疗患者特异性质量保证结果的统计预测模型的临床验证。","authors":"Phillip Wall , Wes Tucker , Thomas Mazur, Frank Marshall, Jonathan Pence, Jon Hansen, Michael Prusator, Matthew Schmidt, Nels Knutson","doi":"10.1016/j.radonc.2025.110934","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate Monte Carlo (MC) secondary dose verification for predicting ionization chamber (IC)-based patient-specific quality assurance (PSQA) measurements for stereotactic body radiotherapy (SBRT) plans.</div></div><div><h3>Methods</h3><div>IC-based PSQA is a trusted method for verifying accurate delivery of absolute dose calculated by the treatment planning system (TPS). However, these measurements are often time-consuming and challenging to perform precisely, especially for small-volume SBRT targets. To investigate an MC-based method as a viable alternative, a logistic regression model was developed to predict measurement-based PSQA results utilizing 400 retrospectively collected IC PSQA measurements across our system. Each clinically approved plan was recalculated using a commercially available secondary MC-based dose calculation platform (Rad MonteCarlo, Radformation, NY). The dose to a contoured volume corresponding to the active IC volume was recorded. Additionally, measurement setup uncertainty was modeled by placing equivalent volumes +/- 2 mm in each cardinal direction. The TPS-calculated value was compared to the average MC-simulated values for all contours. Receiver Operating Characteristic (ROC) analysis was performed on an additional dataset of 328 prospective PSQA measurements to determine MC-based QA prediction thresholds for indicating when physical measurements can be safely avoided.</div></div><div><h3>Results</h3><div>Of the 400 model plans, the percent differences between IC and TPS doses were [Median: −0.06%, Range: −19.6%-4.5%]. The percent differences between IC and MC doses were [Median: 0.17%, Range: −21.8%-5.1%]. When investigating MC against TPS dose for predicting likely PSQA failures, ROC analysis yielded an AUC of 0.76. Based on threshold analysis of the prospective validation dataset, a difference of 1% between MC and TPS calculations resulted in zero false negatives, and would safely reduce the number of required IC measurements by 46%.</div></div><div><h3>Conclusion</h3><div>This study demonstrates feasibility of and a workflow for implementing MC-based secondary dose calculations to reduce the number of physical measurements required for PSQA without compromising safety and quality.</div></div>","PeriodicalId":21041,"journal":{"name":"Radiotherapy and Oncology","volume":"208 ","pages":"Article 110934"},"PeriodicalIF":4.9000,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Clinical validation of statistical predictive model for patient-specific quality assurance outcomes in stereotactic radiotherapy using secondary Monte Carlo dose calculations\",\"authors\":\"Phillip Wall , Wes Tucker , Thomas Mazur, Frank Marshall, Jonathan Pence, Jon Hansen, Michael Prusator, Matthew Schmidt, Nels Knutson\",\"doi\":\"10.1016/j.radonc.2025.110934\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>To evaluate Monte Carlo (MC) secondary dose verification for predicting ionization chamber (IC)-based patient-specific quality assurance (PSQA) measurements for stereotactic body radiotherapy (SBRT) plans.</div></div><div><h3>Methods</h3><div>IC-based PSQA is a trusted method for verifying accurate delivery of absolute dose calculated by the treatment planning system (TPS). However, these measurements are often time-consuming and challenging to perform precisely, especially for small-volume SBRT targets. To investigate an MC-based method as a viable alternative, a logistic regression model was developed to predict measurement-based PSQA results utilizing 400 retrospectively collected IC PSQA measurements across our system. Each clinically approved plan was recalculated using a commercially available secondary MC-based dose calculation platform (Rad MonteCarlo, Radformation, NY). The dose to a contoured volume corresponding to the active IC volume was recorded. Additionally, measurement setup uncertainty was modeled by placing equivalent volumes +/- 2 mm in each cardinal direction. The TPS-calculated value was compared to the average MC-simulated values for all contours. Receiver Operating Characteristic (ROC) analysis was performed on an additional dataset of 328 prospective PSQA measurements to determine MC-based QA prediction thresholds for indicating when physical measurements can be safely avoided.</div></div><div><h3>Results</h3><div>Of the 400 model plans, the percent differences between IC and TPS doses were [Median: −0.06%, Range: −19.6%-4.5%]. The percent differences between IC and MC doses were [Median: 0.17%, Range: −21.8%-5.1%]. When investigating MC against TPS dose for predicting likely PSQA failures, ROC analysis yielded an AUC of 0.76. Based on threshold analysis of the prospective validation dataset, a difference of 1% between MC and TPS calculations resulted in zero false negatives, and would safely reduce the number of required IC measurements by 46%.</div></div><div><h3>Conclusion</h3><div>This study demonstrates feasibility of and a workflow for implementing MC-based secondary dose calculations to reduce the number of physical measurements required for PSQA without compromising safety and quality.</div></div>\",\"PeriodicalId\":21041,\"journal\":{\"name\":\"Radiotherapy and Oncology\",\"volume\":\"208 \",\"pages\":\"Article 110934\"},\"PeriodicalIF\":4.9000,\"publicationDate\":\"2025-05-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiotherapy and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0167814025002294\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiotherapy and Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0167814025002294","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
Clinical validation of statistical predictive model for patient-specific quality assurance outcomes in stereotactic radiotherapy using secondary Monte Carlo dose calculations
Purpose
To evaluate Monte Carlo (MC) secondary dose verification for predicting ionization chamber (IC)-based patient-specific quality assurance (PSQA) measurements for stereotactic body radiotherapy (SBRT) plans.
Methods
IC-based PSQA is a trusted method for verifying accurate delivery of absolute dose calculated by the treatment planning system (TPS). However, these measurements are often time-consuming and challenging to perform precisely, especially for small-volume SBRT targets. To investigate an MC-based method as a viable alternative, a logistic regression model was developed to predict measurement-based PSQA results utilizing 400 retrospectively collected IC PSQA measurements across our system. Each clinically approved plan was recalculated using a commercially available secondary MC-based dose calculation platform (Rad MonteCarlo, Radformation, NY). The dose to a contoured volume corresponding to the active IC volume was recorded. Additionally, measurement setup uncertainty was modeled by placing equivalent volumes +/- 2 mm in each cardinal direction. The TPS-calculated value was compared to the average MC-simulated values for all contours. Receiver Operating Characteristic (ROC) analysis was performed on an additional dataset of 328 prospective PSQA measurements to determine MC-based QA prediction thresholds for indicating when physical measurements can be safely avoided.
Results
Of the 400 model plans, the percent differences between IC and TPS doses were [Median: −0.06%, Range: −19.6%-4.5%]. The percent differences between IC and MC doses were [Median: 0.17%, Range: −21.8%-5.1%]. When investigating MC against TPS dose for predicting likely PSQA failures, ROC analysis yielded an AUC of 0.76. Based on threshold analysis of the prospective validation dataset, a difference of 1% between MC and TPS calculations resulted in zero false negatives, and would safely reduce the number of required IC measurements by 46%.
Conclusion
This study demonstrates feasibility of and a workflow for implementing MC-based secondary dose calculations to reduce the number of physical measurements required for PSQA without compromising safety and quality.
期刊介绍:
Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.